Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma

(2020) Nisha S. Joseph et al.   JOURNAL OF CLINICAL ONCOLOGY

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

(2020) Shaji Kumar et al.   JOURNAL OF CLINICAL ONCOLOGY

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma

(2019) Aurore Perrot et al.   JOURNAL OF CLINICAL ONCOLOGY

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

(2019) Thierry Facon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

(2019) Philippe Moreau et al.   LANCET

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma

(2019) Laura Rosiñol et al.   BLOOD

Development of a prognostic model for overall survival in multiple myeloma using the Connect ® MM Patient Registry

(2019) Howard R. Terebelo et al.   BRITISH JOURNAL OF HAEMATOLOGY

Drug response prediction in high-risk multiple myeloma

(2018) A.J. Vangsted et al.   GENE

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

(2018) Brian A. Walker et al.   LEUKEMIA

RNA-Seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

(2018) Michael A. Chapman et al.   BLOOD

Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects

(2018) Joske Ubels et al.   Nature Communications

Towards personalized treatment in multiple myeloma based on molecular characteristics

(2018) Charlotte Pawlyn et al.   BLOOD

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma

(2018) M. Hasib Sidiqi et al.   Blood Cancer Journal

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

(2017) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit

(2017) Jing Wang et al.   NUCLEIC ACIDS RESEARCH

Is the revised International staging system for myeloma valid in a real world population?

(2016) Ieuan Walker et al.   BRITISH JOURNAL OF HAEMATOLOGY

Gene Expression Profiles in Myeloma: Ready for the Real World?

(2016) Raphael Szalat et al.   CLINICAL CANCER RESEARCH

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma

(2016) Efstathios Kastritis et al.   HAEMATOLOGICA

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma

(2016) Efstathios Kastritis et al.   HAEMATOLOGICA

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System

(2015) R. Kuiper et al.   BLOOD

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

(2015) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

(2015) Brian A. Walker et al.   JOURNAL OF CLINICAL ONCOLOGY

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs

(2015) T Narita et al.   Blood Cancer Journal

Novel strategies to target the ubiquitin proteasome system in multiple myeloma

(2015) Susanne Lub et al.   Oncotarget

The future of autologous stem cell transplantation in myeloma

(2014) F. van Rhee et al.   BLOOD

Gene expression profile alone is inadequate in predicting complete response in multiple myeloma

(2014) S B Amin et al.   LEUKEMIA

p53 haploinsufficiency and functional abnormalities in multiple myeloma

(2014) P J Teoh et al.   LEUKEMIA

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

(2013) B Hebraud et al.   LEUKEMIA

IMWG consensus on risk stratification in multiple myeloma

(2013) W J Chng et al.   LEUKEMIA

Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks

(2012) Cole Trapnell et al.   Nature Protocols

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

(2011) K D Boyd et al.   LEUKEMIA

Random survival forests

(2008) Hemant Ishwaran et al.   Annals of Applied Statistics